105 related articles for article (PubMed ID: 9059648)
1. Structural studies of aldo-keto reductase inhibition.
Wilson DK; Nakano T; Petrash JM; Quiocho FA
Adv Exp Med Biol; 1997; 414():435-42. PubMed ID: 9059648
[No Abstract] [Full Text] [Related]
2. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Wilson DK; Tarle I; Petrash JM; Quiocho FA
Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9847-51. PubMed ID: 8234324
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
5. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
Singh SB; Malamas MS; Hohman TC; Nilakantan R; Carper DA; Kitchen D
J Med Chem; 2000 Mar; 43(6):1062-70. PubMed ID: 10737739
[TBL] [Abstract][Full Text] [Related]
7. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
8. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
9. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
10. Structure of porcine aldehyde reductase holoenzyme.
el-Kabbani O; Judge K; Ginell SL; Myles DA; DeLucas LJ; Flynn TG
Nat Struct Biol; 1995 Aug; 2(8):687-92. PubMed ID: 7552731
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
Kumar H; Shah A; Sobhia ME
J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
[TBL] [Abstract][Full Text] [Related]
12. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Kotani T; Nagaki Y; Ishii A; Konishi Y; Yago H; Suehiro S; Okukado N; Okamoto K
J Med Chem; 1997 Feb; 40(5):684-94. PubMed ID: 9057855
[TBL] [Abstract][Full Text] [Related]
13. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolylbenzothiazole derivatives as aldose reductase inhibitors.
Zaher N; Nicolaou I; Demopoulos VJ
J Enzyme Inhib Med Chem; 2002 Apr; 17(2):131-5. PubMed ID: 12420760
[No Abstract] [Full Text] [Related]
15. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Podjarny A
Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily.
Ye Q; Hyndman D; Li X; Flynn TG; Jia Z
Proteins; 2000 Jan; 38(1):41-8. PubMed ID: 10651037
[TBL] [Abstract][Full Text] [Related]
17. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Mylari BL; Larson ER; Beyer TA; Zembrowski WJ; Aldinger CE; Dee MF; Siegel TW; Singleton DH
J Med Chem; 1991 Jan; 34(1):108-22. PubMed ID: 1899452
[TBL] [Abstract][Full Text] [Related]
18. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O
Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944
[TBL] [Abstract][Full Text] [Related]
19. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
20. Exploring structural requirements for aldose-reductase inhibition by 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues: Fujita-Ban and Hansch approach.
Soni LK; Kaskhedikar SG
Arch Pharm (Weinheim); 2006 Jun; 339(6):327-31. PubMed ID: 16622827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
